Linking Ubiquitin Research to Drug Discovery

Home » News & Events

Ubiquigent announces £0.5m funding and strengthens board of directors with key appointment

Posted on September 18th, 2014 in News
Dundee, UK, 18th Sept 2013: Ubiquigent Limited a company specialising in ubiquitin cell-signalling system drug discovery capabilities and services, today announced it has received £0.5 million in funding from IP Group plc and the Scottish Investment Bank, the investment arm of… Read more

Ubiquigent Ltd announces the appointment of Cosmo Bio USA Inc as their sole north American product distributor

Posted on January 17th, 2013 in News
Dundee, UK, 17th January 2013 - Ubiquigent Ltd. today announced the appointment of Cosmo Bio USA Inc. as their sole North American Distributor. Commenting on the appointment Ubiquigent's Managing Director Dr Jason Brown said; “Ubiquigent are delighted to be appointing Cosmo Bio… Read more

Ubiquigent Ltd announces expansion of its DUBprofiler™ service

Posted on November 27th, 2012 in News
Ubiquigent Ltd announces significant expansion of its DUBprofiler™ compound selectivity service enabling the profiling of drug lead compounds versus 35 deubiquitylase enzymes. Dundee, UK, 27th November 2012 - Ubiquigent Ltd. today announced the significant expansion of their DUBprofiler service compound profiling panel from 23… Read more

Harvard Medical School’s Prof. Alfred Goldberg delivers inaugural speech

Posted on June 14th, 2012 in News
Harvard Medical School's Prof. Alfred Goldberg delivers inaugural speech at Ubiquigent, Medical Research Council, University of Dundee sponsored ubiquitin system drug discovery lecture Dundee, UK, 14th June 2012 - Ubiquigent Ltd was honoured today to have Professor Alfred Goldberg, Professor of… Read more

Stemgent announces formation of Ubiquigent, a new UK-listed biotechnology company based in Dundee, Scotland

Posted on March 3rd, 2010 in News
New Venture co-founded with Professor Sir Philip Cohen to Focus on the Ubiquitin Proteasome Pathway, a Key Cell Signalling System with Significant Drug Discovery Potential Boston, MA, San Diego, CA, USA, March 3, 2010 - Stemgent, Inc., a biotechnology company… Read more